{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observational+Phase+2%2C+Group+II&page=2", "query": { "intervention": "Observational Phase 2, Group II", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Observational+Phase+2%2C+Group+II&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T04:34:39.172Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06179888", "title": "Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Skeletal Survey X-Ray", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2024-08-27", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 74, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 55 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179888" }, { "nct_id": "NCT00719303", "title": "Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Behavioral Dietary Intervention", "type": "BEHAVIORAL" }, { "name": "Compliance Monitoring", "type": "BEHAVIORAL" }, { "name": "Counseling", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1070, "start_date": "2012-06-18", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-02-19", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 687, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719303" }, { "nct_id": "NCT01036009", "title": "A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Biphenotypic Leukemia", "Pre-leukemic Syndromes", "Monosomy 7", "Bone Marrow Clonal Malformations", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Withdrawal of immunosuppression and donor lymphocyte infusion", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 43, "start_date": "2009-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-06-23", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 2, "location_summary": "San Francisco, California • St. Petersburg, Florida", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01036009" }, { "nct_id": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "Gefitinib", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 247, "start_date": "2019-06-25", "completion_date": "2025-05-06", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944772" }, { "nct_id": "NCT01968226", "title": "TRACER RGD-K5 Carotid Plaque Imaging Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carotid Artery Disease", "Carotid Stenosis" ], "interventions": [ { "name": "[F-18] RDG-K5", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2013-11", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-09-12", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01968226" }, { "nct_id": "NCT01309230", "title": "A Trial of FANG™ Vaccine for Participants With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Vigil™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 39, "start_date": "2011-03-08", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 7, "location_summary": "West Palm Beach, Florida • Lebanon, New Hampshire • Hackensack, New Jersey + 3 more", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309230" }, { "nct_id": "NCT00006363", "title": "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Erythroid Leukemia (M6)", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Childhood Acute Basophilic Leukemia", "Childhood Acute Eosinophilic Leukemia", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Childhood Myelodysplastic Syndromes", "de Novo Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia", "Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "clinical observation", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "15 Years to 59 Years" }, "enrollment_count": 720, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006363" }, { "nct_id": "NCT00027846", "title": "Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Mesna", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 378, "start_date": "2003-08", "completion_date": "2016-03-31", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 140, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027846" }, { "nct_id": "NCT00022334", "title": "Vaccine Therapy in Treating Patients With Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "AFP", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2001-01", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022334" }, { "nct_id": "NCT04611087", "title": "Self-monitoring Focus Groups With Vibrant Lives Pasadena Participants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obesity-Related Malignant Neoplasm" ], "interventions": [ { "name": "Discussion", "type": "BEHAVIORAL" }, { "name": "Interview", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 39, "start_date": "2018-07-03", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-28T04:34:39.172Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04611087" } ] }